Capital Performance Advisors’s ProKidney PROK Stock Holding History

Capital Performance Advisors’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-279	Closed	-$536	–	2040
2024 Q3	$536	Buy	+279	New	+$633	﹤0.01%	2214

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Performance Advisors's PROK Position: Q4 2024 in Review

Capital Performance Advisors sold out of ProKidney (PROK) in Q4 2024, closing a stake of 279 shares — an estimated $536 sold.

Capital Performance Advisors first reported a position in PROK in Q3 2024 and held it in 1 quarter. The position peaked at $536 in Q3 2024. 74 funds tracked by Wall St. Rank hold PROK as of Q4 2024.

Capital Performance Advisors reported no remaining ProKidney position as of Q4 2024 after selling out during the quarter.
Capital Performance Advisors sold 279 ProKidney shares in Q4 2024, an estimated $536.
Capital Performance Advisors first reported a position in ProKidney in Q3 2024 and held it in 1 quarter.
Capital Performance Advisors's ProKidney position peaked at $536 in Q3 2024.
74 funds tracked by Wall St. Rank held ProKidney as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.